Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + Bevacizumab + FOLFOX-HAIC + TACE as Neoadjuvant Therapy for Resectable HCC
NCT07522411Phase 2Not yet recruiting
- Start
- Apr 2026
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Orthosteric Ligands
01
Overview
A Phase 2 trial of sintilimab, bevacizumab, oxaliplatin, folinic acid, fluorouracil in hepatocellular carcinoma (HCC). Planned start Apr 2026; status: not yet recruiting.
02
Drugs
sintilimabbevacizumaboxaliplatinfolinic acidfluorouracil
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07522411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07522411.